Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

PBHยทNYSE

$45.44

-1.1%
HealthcareMedical - Distribution

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

At a Glance

Live Snapshot
Market Cap$2.15B
EPS3.9300
P/E Ratio11.56
Earnings Date08/06/2026
3Y-3.0%
5Y+15.0%
10Y+23.0%
3Y-331.0%
5Y+16.0%
10Y+174.0%
3Y+12.0%
5Y+9.0%
10Y+74.0%
Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc. Profit Bridge

PBH ยท NYSE
Revenue1.09B
Cost of Goods Sold (493.13M)
Gross Profit595.58M
Operating Expenses (286.17M)
Operating Income309.41M
Interest Expense (42.34M)
Other Income/Expense-51.91M
Pretax Income257.50M
Income Tax (67.19M)
Net Income190.30M
Net Income
190.30M

Profitability Analysis

Gross Margin

54.7%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

28.4%

Outstanding operational efficiency. The company generates substantial profit from core operations.

Net Profit Margin

17.5%

Strong net margins indicate efficient operations and favorable tax/interest management.

Effective Tax Rate

26.1%

Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.

Profitability Insight

Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.

Prestige Consumer Healthcare Inc. Income Statement

PBH โ€ข NYSE

Prestige Consumer Healthcare Inc. Income StatementMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010Mar 2009Mar 2008Mar 2007
REVENUE
1.1B
1.1B
1.1B
1.1B
1.1B
943.4M
963M
975.8M
1B
882.1M
806.2M
714.6M
601.9M
623.6M
441.1M
336.5M
302M
312.7M
326.6M
318.6M
GROSS PROFIT
(493.1M)
(503.3M)
(500.9M)
(502.4M)
(466.2M)
(395.9M)
(410.8M)
(420.2M)
(464.7M)
(381.8M)
(339M)
(308.4M)
(261.8M)
(276.4M)
(213.7M)
(165.6M)
(144.6M)
(149.4M)
(158.1M)
(153.1M)
595.6M
634.5M
624.4M
625.3M
620.6M
547.5M
552.2M
555.6M
576.5M
500.3M
467.2M
406.2M
340.1M
347.2M
227.4M
170.9M
157.4M
163.3M
168.5M
165.5M
OPERATING INCOME
(286.2M)
(297.7M)
(282M)
(647.7M)
(290.7M)
(250.1M)
(261.1M)
(259.9M)
(360.6M)
(242.9M)
(206.9M)
(198.7M)
(151.4M)
(155.3M)
(124.6M)
(94.7M)
(76M)
(81.2M)
(77.1M)
(70.8M)
(265.2M)
(263.9M)
(259.5M)
(252.4M)
(264.8M)
(223.7M)
(236.3M)
(232.8M)
(332.2M)
(217.5M)
(183.2M)
(180.9M)
(137.9M)
(142.1M)
(113.8M)
(84.9M)
(65.4M)
(70M)
(66.1M)
(60.4M)
309.4M
336.8M
342.4M
-22.4M
329.9M
297.4M
291.2M
67.5M
215.9M
205.6M
260.3M
207.6M
188.6M
191.9M
102.8M
76.1M
78.7M
-167.5M
91.4M
94.7M
PRE-TAX INCOME
(42.3M)
(47.6M)
(67.2M)
(69.2M)
(64.3M)
(82.3M)
(96.6M)
(105.3M)
(106.3M)
(93.5M)
(85.3M)
(81.3M)
(68.6M)
(84.4M)
(41.3M)
(27.3M)
(22.9M)
(28.6M)
(0.0)
(0.0)
0.0
-47.6M
-67.2M
-69.2M
-64.3M
-82.3M
-96.2M
-105.1M
-105.9M
-93.3M
-85.2M
-81.2M
-68.6M
-84.4M
-41.3M
-27.3M
-22.9M
-28.4M
0.0
0.0
(20.9M)
(33.8M)
(22.6M)
(395.3M)
(25.9M)
(26.4M)
(24.8M)
-476K
(28.4M)
(25.4M)
(23.7M)
(17.7M)
(13.5M)
(13.2M)
(10.7M)
(9.9M)
(10.6M)
(11.2M)
(11M)
(10.4M)
-51.9M
-52.6M
-66.4M
-71.5M
-67.5M
-93.3M
-100M
-105.6M
-108.4M
-94.8M
-103.1M
-80.1M
-86.9M
-85.9M
-41.7M
-27.6M
-25.6M
-28.4M
-37.2M
-39.5M
257.5M
284.2M
276M
-93.9M
262.5M
204.1M
191.2M
-38.1M
107.1M
110.9M
157.2M
127.5M
101.7M
106M
61.2M
48.5M
53.1M
-196M
54.2M
55.2M
NET INCOME
(67.2M)
(69.6M)
(66.7M)
-11.6M
(57.1M)
(39.4M)
(48.9M)
-2.3M
-232.5M
(41.5M)
(57.3M)
(49.2M)
(29.1M)
(40.5M)
(23.9M)
(19.3M)
(21.8M)
-9.2M
(20.3M)
(19.1M)
190.3M
214.6M
209.3M
-82.3M
205.4M
164.7M
142.3M
-35.8M
339.6M
69.4M
99.9M
78.3M
72.6M
65.5M
37.2M
29.2M
32.1M
-186.8M
33.9M
36.1M

SEC Filings

PBH - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-K

10-K 2026 FY

FY

May 14, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 13, 2026
May 13, 2026
2026
8-K

8-K 2026

N/A

March 20, 2026
March 19, 2026
2026
10-Q

10-Q 2025 Q4

Q4

February 05, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 05, 2026
February 05, 2026
2026
10-Q

10-Q 2025 Q3

Q3

November 06, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 06, 2025
November 06, 2025
2025
10-Q

10-Q 2025 Q2

Q2

August 07, 2025
June 30, 2025
2025
8-K

8-K 2025

N/A

August 07, 2025
August 07, 2025
2025
DEF 14A

DEF 14A 2025

N/A

June 27, 2025
August 05, 2025
2025
Showing 1 to 10 of 325 filings